Found 3 articles for: "pembrolizumab"
Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
May 2026 | Volume 25 | Issue 5 | Original Article | 421 | Copyright © May 2026
Background: Melanoma is the leading cause of skin-cancer-related mortality worldwide. Anti-programmed cell death protein-1 therapies, including pembrolizumab, play a critical rol...
Read MorePembrolizumab as an Off-Label Treatment of Facial Angiosarcoma: A Case Report
May 2026 | Volume 25 | Issue 5 | Case Reports | 471 | Copyright © May 2026
Summary of Case: We report an atypical case of cutaneous angiosarcoma presenting as unilateral nasal swelling in an elderly male. The lesion was unresponsive to topical and antib...
Read MoreSuccessful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy
June 2022 | Volume 21 | Issue 6 | Case Reports | 668 | Copyright © June 2022
Immune checkpoint inhibitors including programmed death protein 1 inhibitors show great therapeutic benefit for numerous advanced malignancies but can cause a spectrum of immune-related adverse events...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.